Myelodysplasia, megakaryocytes, and methylation

Leukemia Research

Volumn 28, Issue 8, 2004, Pages 775-776

  Steensma, David P ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIMETABOLITE; AZACITIDINE; CYTARABINE; DEOXYCYTIDINE;

CANCER PATIENT; CELL GROWTH; CHROMATIN STRUCTURE; CYTOPENIA; CYTOTOXICITY; DNA METHYLATION; DRUG INDICATION; EDITORIAL; EPIGENETICS; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; MEGAKARYOCYTE; MYELODYSPLASIA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; HUMANS; MEGAKARYOCYTES; MYELODYSPLASTIC SYNDROMES;

EID: 2942527442     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.01.003     Document Type: Editorial

References (20)

1. Mittelman M., Zeidman A. Platelet function in the myelodysplastic syndromes. Int. J. Hematol. 71:2000;95-98
2. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin. Hematol. 37:2000;3-10
3. Brown J.R., Demetri G.D. Challenges in the development of platelet growth factors: low expectations for low counts. Curr. Hematol. Rep. 1:2002;110-118
4. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high risk myelodysplastic syndromes. Leukemia Research 2004;28:785-90.
5. Wijermans P.W., Krulder J.W., Huijgens P.C., Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 11:1997;1-5
6. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956-962
7. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (Decitabine) in hematopoietic malignancies. Blood, epub ahead of print 6 November 2003.
8. Decitabine: 2′-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D, 2003;4:352-8.
9. Hatada I., Hayashizaki Y., Hirotsune S., Komatsubara H., Mukai T. A genomic scanning method for higher organisms using restriction sites as landmarks. Proc. Natl. Acad. Sci. U.S.A. 88:1991;9523-9527
10. van Groeningen C.J., Leyva A., O'Brien A.M., Gall H.E., Pinedo H.M. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46:1986;4831-4836
11. Leone G., Teofili L., Voso M.T., Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 87:2002;1324-1341
12. Jones P.A., Taylor S.M. Cellular differentiation. Cell. 20:1980;85-93
13. Momparler R.L., Onetto-Pothier N., Momparler L.F. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype. Leuk. Res. 14:1990;755-760
14. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20:2002;2429-2440
15. Wilson V.L., Jones P.A., Momparler R.L. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 43:1983;3493-3496
16. Paz M.F., Fraga M.F., Avila S., Guo M., Pollan M., Herman J.G., et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 63:2003;1114-1121
17. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood. 100:2002;2957-2964
18. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with {alpha} thalassemia (ATMDS) convey a more severe hematological phenotype than germline ATRX mutations. Blood, epub ahead of print 30 October 2003.
19. Gibbons R.J., McDowell T.L., Raman S., O'Rourke D.M., Garrick D., Ayyub H., et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet. 24:2000;368-371
20. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107